Arthur Fratamico, Radiant Biotherapeutics CEO
September 11, 2024 07:00 AM EDT
Financing
Startups

Ra­di­ant Bio snags $35M for an­ti­body plat­form, with GSK and Re­gen­eron part­ner­ships

Kyle LaHucik

Senior Reporter

A drug de­vel­op­er aim­ing to cre­ate more po­tent, ef­fec­tive an­ti­bod­ies un­veiled a $35 mil­lion Se­ries A on Wednes­day with the sup­port of the Bill …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times